<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33495">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670577</url>
  </required_header>
  <id_info>
    <org_study_id>IMPACt</org_study_id>
    <nct_id>NCT02670577</nct_id>
  </id_info>
  <brief_title>Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry</brief_title>
  <acronym>IMPACt</acronym>
  <official_title>Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agendia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agendia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scope of this study is to measure the impact of MammaPrint on treatment in Hormone
      Receptor (HR)-positive HER2-negative breast cancer patients.

      In addition, the impact of MammaPrint on treatment in patients with T1a/T1b and pN0/pN1 (up
      to 1 node), Triple Negative or HER2-positive tumors will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will have their tumor sample analyzed for MammaPrint, BluePrint and
      TargetPrint. Patients cannot start treatment before the MammaPrint and BluePrint result is
      received and taken into consideration for the treatment plan. The clinical data are to be
      entered online. There will be 2 Case Report Forms (CRFs). Baseline clinical data and
      physician chemotherapy intention before knowing the MammaPrint and BluePrint result will be
      entered in CRF 1. After completion of CRF1, the MammaPrint and BluePrint result will be
      released. CRF2 will be completed after the final treatment decision has been made. This CRF
      will capture physician chemotherapy intention after the MammaPrint and BluePrint result and
      the impact of these results.

      A sample size of 331 patients is required to detect a 25% overall treatment change (5%
      significance and 95% power) in stage I and II HR-positive, HER2-negative patients receiving
      adjuvant therapy.

      In addition at least 50 T1a/bN0/1 (up to 1 node) Triple Negative, at least 50 T1a/bN0/1 (up
      to 1 node) HER2-positive breast cancer patients, and at least 50 patients receiving
      neoadjuvant therapy will be enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Months</target_duration>
  <primary_outcome>
    <measure>Change in Treatment Decision</measure>
    <time_frame>6 weeks</time_frame>
    <description>Compare treatment decision before and after test results.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">481</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>stage I or II HR-positive, HER2-negative</arm_group_label>
    <description>Histologically proven invasive stage I and II breast cancer and Hormone Receptor positive &amp; HER2 negative
&amp; Axillary lymph node status: 0-3 involved</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2+</arm_group_label>
    <description>Histologically proven invasive T1a or T1b breast cancer
&amp; Hormone receptor negative or positive
&amp; HER2 positive
&amp; Axillary lymph node status: 0-1 involved</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Negative</arm_group_label>
    <description>Histologically proven invasive T1a or T1b breast cancer
&amp; Hormone receptor negative
&amp; HER2 negative
&amp; Axillary lymph node status: 0-1 involved</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant</arm_group_label>
    <description>Stage I or II patients receiving neoadjuvant therapy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Stage I or II HR-positive, HER2-negative breast cancer patients AND T1a/b, N0/N1 (up to 1
        node) Triple Negative, or HER2-positive breast cancer patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible to receive chemotherapy and endocrine therapy as defined by a good Karnofsky
             index (≥80) and no hematologic, cardiologic or hepatic contraindications, nor any
             impeding comorbidity

          -  Informed consent form signed on the same day or before enrollment

          -  ≥ 18 years of age at time of consent Per study arm

          -  Histologically proven invasive stage I and II breast cancer and Hormone Receptor
             positive (ER+ PR-, ER- PR+ or ER+ PR+) according to local standards &amp; HER2 negative:
             IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)

        IMPACt study; version 1 2015 September 1 Page 10 Axillary lymph node status: 0-3 involved
        (macro metastases i.e. &gt;2mm OR micro metastases i.e. &gt;0.2-2mm)

        OR

        Histologically proven invasive T1a or T1b breast cancer &amp; Hormone receptor negative (ER-
        and PR-) according to local standards &amp; HER2 negative: IHC 0-1+, or FISH or other ISH
        non-amplified (locally assessed)

        &amp; Axillary lymph node status: 0-1 involved (macro metastases i.e. &gt;2mm OR micro metastases
        i.e. &gt;0.2-2mm)

        OR

        Histologically proven invasive T1a or T1b breast cancer

        &amp; Hormone receptor negative or positive (ER-PR-, ER+PR-, ER-PR+, ER+PR+) according to
        local standards

        &amp; HER2 positive: IHC 3+, or FISH or other ISH amplified (locally assessed)

        &amp; Axillary lymph node status: 0-1 involved (macro metastases i.e. &gt;2mm OR micro metastases
        i.e. &gt;0.2-2mm)

        Exclusion Criteria:

          -  Previous diagnosis of breast malignancy unless disease free for 10 years

          -  Metastatic disease

          -  Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails QA or QC
             criteria

          -  Women who have started or completed adjuvant chemotherapy or neo-adjuvant
             chemotherapy for current breast cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Untch, M.S.</last_name>
    <phone>(412) 770-6906</phone>
    <email>sarah.untch@agendia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Desert Regional Medical Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Fortiche</last_name>
      <email>claudia.fortiche@tenethealth.com</email>
    </contact>
    <investigator>
      <last_name>Laura Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Conte</last_name>
      <email>dmc238@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Reshma Mahtani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Women's Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Connie Nickerson, LPN</last_name>
      <email>connie.nickerson@baycare.org</email>
    </contact>
    <investigator>
      <last_name>Robert Gabordi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cancer Center at DeKalb Medical</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruthie Sweat</last_name>
      <email>Ruthie.sweat@dekalbmedical.org;</email>
    </contact>
    <investigator>
      <last_name>Jayanthi Srinivasiah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cadence Cancer Center</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudine Gamster</last_name>
      <email>Claudine.Gamster@CadenceHealth.org</email>
    </contact>
    <investigator>
      <last_name>John Ayers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Merrillville</city>
        <state>Indiana</state>
        <zip>46410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Reed</last_name>
      <email>breed@methodisthospitals.org</email>
    </contact>
    <investigator>
      <last_name>Bharat Barai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Healthcare System</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Shields</last_name>
      <email>mshields@comhs.org</email>
    </contact>
    <investigator>
      <last_name>Mohamad Kassar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Maryland Health System</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mildred Seletyn</last_name>
      <email>mseletyn@wmhs.com</email>
    </contact>
    <investigator>
      <last_name>Blanche Mavromatis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harsha Trivedi</last_name>
      <email>Harsha.trivedi@sparrow.org</email>
    </contact>
    <investigator>
      <last_name>Gordon Srkalovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Essex Oncology</name>
      <address>
        <city>Belleville</city>
        <state>New Jersey</state>
        <zip>07109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Johnstone</last_name>
      <email>trials@essexoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Orsini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Lynne Tarquini</last_name>
      <email>MaryLynne.Tarquini@RoswellPark.org</email>
    </contact>
    <investigator>
      <last_name>Ellis Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Farmer</last_name>
      <email>Cathy.Farmer@akrongeneral.org</email>
    </contact>
    <investigator>
      <last_name>Esther Rehmus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisha Hancock</last_name>
      <email>Alisha-hancock@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>William Dooley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Torres</last_name>
      <email>jtorres@stmaryhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Christine Armetta</last_name>
      <email>carmetta@stmaryhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Reilly, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Clair Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colin Smith</last_name>
      <email>colin.smith@stclair.org</email>
    </contact>
    <investigator>
      <last_name>Raye Budway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Cancer Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan DeBartolo</last_name>
      <email>jan.bartolo@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Rubina Qamar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia St. Mary's</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Brown, RN</last_name>
      <email>kathleen.brown@columbia-stmarys.or</email>
    </contact>
    <investigator>
      <last_name>Varsha Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 23, 2017</lastchanged_date>
  <firstreceived_date>January 27, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I</keyword>
  <keyword>stage II</keyword>
  <keyword>HER2 positive</keyword>
  <keyword>Triple Negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
